Published in J Am Coll Cardiol on October 05, 2010
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm (2011) 2.01
Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. Pharmacotherapy (2012) 1.46
American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation (2011) 0.97
The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovasc Res (2015) 0.95
Mechanisms of termination and prevention of atrial fibrillation by drug therapy. Pharmacol Ther (2011) 0.94
Ryanodine receptor inhibition potentiates the activity of Na channel blockers against spontaneous calcium elevations and delayed afterdepolarizations in Langendorff-perfused rabbit ventricles. Heart Rhythm (2012) 0.94
Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol (2011) 0.93
Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967. Heart Rhythm (2013) 0.92
Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine. Circ Arrhythm Electrophysiol (2012) 0.89
Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther (2013) 0.89
Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries. Clin Res Cardiol (2014) 0.85
Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther (2011) 0.83
Novel anti-arrhythmic medications in the treatment of atrial fibrillation. Curr Cardiol Rev (2012) 0.82
Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation. Europace (2012) 0.82
Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. Circ Heart Fail (2014) 0.79
Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin Med Insights Cardiol (2013) 0.78
The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS. Curr Cardiol Rev (2014) 0.78
PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers. J Am Coll Cardiol (2016) 0.77
New treatment options for late Na current, arrhythmias, and diastolic dysfunction. Curr Heart Fail Rep (2012) 0.77
Atrial arrhythmogenicity of KCNJ2 mutations in short QT syndrome: Insights from virtual human atria. PLoS Comput Biol (2017) 0.77
Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis. Int J Cardiol (2016) 0.76
Ranolazine for atrial fibrillation: buy one get three beneficial mechanisms! Eur J Heart Fail (2012) 0.76
Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation. Future Cardiol (2011) 0.75
Current issues in atrial fibrillation. ISRN Cardiol (2012) 0.75
Update on ranolazine in the management of angina. Vasc Health Risk Manag (2014) 0.75
Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization. Pharmacol Ther (2016) 0.75
Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation. Exp Anim (2017) 0.75
Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation. J Am Heart Assoc (2017) 0.75
Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med (1998) 23.22
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm (2005) 3.55
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol (2009) 3.54
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J (2003) 1.63
Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol (2006) 1.60
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol (2001) 1.30
New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol (2010) 1.27
The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J (2008) 1.25
Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol (2002) 1.24
Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol (2007) 1.21
The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J (2009) 1.21
Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone. Circulation (1999) 1.20
Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol (2003) 1.20
SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol (1995) 1.13
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol (2009) 1.13
Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs (2009) 1.12
Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol (2009) 1.05
In vitro effects of acute amiodarone and dronedarone on epicardial, endocardial, and M cells of the canine ventricle. J Cardiovasc Pharmacol Ther (2007) 0.90
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm (2010) 2.79
Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation (2012) 2.78
Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation (2003) 2.74
The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol (2010) 2.56
Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol (2006) 2.56
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol (2008) 2.49
Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm (2007) 2.44
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol (2008) 2.42
Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med (2008) 2.38
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm (2011) 2.26
Fever-induced Brugada pattern: how common is it and what does it mean? Heart Rhythm (2013) 2.25
Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation (2002) 2.23
Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther (2006) 2.21
The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell (2005) 2.19
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol (2003) 2.12
An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol (2008) 2.09
Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm (2004) 2.07
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol (2010) 2.04
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03
Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm (2011) 2.02
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm (2011) 2.01
A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res (2008) 2.01
Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci (2003) 1.97
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol (2004) 1.94
Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest (2006) 1.94
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet (2009) 1.87
Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm (2011) 1.87
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation (2004) 1.86
Cellular basis for the monophasic action potential. Which electrode is the recording electrode? Cardiovasc Res (2004) 1.85
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation (2002) 1.84
Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm (2005) 1.83
Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol (2006) 1.78
The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol (2010) 1.78
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol (2007) 1.77
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm (2006) 1.74
Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol (2004) 1.69
Reactive oxygen species-activated Ca/calmodulin kinase IIδ is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circ Res (2011) 1.69
Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm (2008) 1.69
Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice. Am J Physiol Cell Physiol (2011) 1.69
Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther (2004) 1.66
Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res (2002) 1.64
A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging (2009) 1.63
Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J (2005) 1.61
Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation (2011) 1.60
Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol (2006) 1.60
A novel mutation in the HCN4 gene causes symptomatic sinus bradycardia in Moroccan Jews. J Cardiovasc Electrophysiol (2010) 1.60
Early repolarization syndrome: a decade of progress. J Electrocardiol (2013) 1.59
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol (2010) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol (2011) 1.55
Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. Am J Physiol Heart Circ Physiol (2004) 1.53
Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol (2004) 1.52
CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure. Cardiovasc Drugs Ther (2007) 1.52
Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm (2009) 1.51
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 1.51
Deranged sodium to sudden death. J Physiol (2015) 1.51
Pathophysiology and pharmacology of the cardiac "late sodium current.". Pharmacol Ther (2008) 1.50
Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation (2005) 1.50
Functional expression of "cardiac-type" Nav1.5 sodium channel in canine intracardiac ganglia. Heart Rhythm (2006) 1.50
Fever and Brugada syndrome. Pacing Clin Electrophysiol (2002) 1.48
Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. JACC Cardiovasc Imaging (2009) 1.48
Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm (2012) 1.46
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol (2003) 1.46
Abnormal expression of cardiac neural crest cells in heart development: a different hypothesis for the etiopathogenesis of Brugada syndrome. Heart Rhythm (2006) 1.46